Fibroblast activation protein (FAP) is highly upregulated in the stroma of >90Â % of epithelial cancers with restricted expression in normal tissues, making it an attractive drug target.
Efforts by numerous laboratories developing FAP-targeted radiopharmaceuticals have been significant and led to the development of promising diagnostic agents (e.g., [
